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Abstract 
 
 
The reversible nature of early type 2 diabetes has been demonstrated in in vivo human 
studies. The associated pathophysiologic studies have demonstrated return to normal of the 
elevated intra-pancreatic triglyceride content simultaneously with restoration of first phase 
insulin secretion. Recent studies of beta-cell biology both in vivo and in vitro have 
established that the beta-cell loses differentiated characteristics including glucose-mediated 
insulin secretion under metabolic stress. Critically, the beta-cell de-differentiation produced 
by long term excess nutrient supply is reversible. However, in type 2 diabetes of duration 
greater than 10 years the cellular changes appear to pass a point of no return. This review 
summarizes the evidence that early type 2 diabetes can be regarded as a reversible beta-cell 
response to chronic positive calorie balance. 
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Until recently, the pathophysiology of type 2 diabetes was believed to be characterised by 
progressive, irreversible loss of pancreatic insulin secretion [1] mediated by apoptosis of 
pancreatic beta-cells [2]. Now that weight loss has been shown to bring about restoration of 
beta-cell function and reversal of diabetes, fundamental reappraisal of the mechanisms 
underlying beta-cell dysfunction is required. The recent in vivo and in vitro studies will be 
reviewed, together with the evidence that the underlying, potentially reversible, beta-cell 
failure is related to dedifferentiation rather than beta cell death. 
 
 
 
Etiological drivers of type 2 diabetes 
 
 
Population data demonstrate major increases or decreases in incidence of type 2 diabetes 
secondary to food excess or scarcity. This was documented in the UK during the first and 
second World Wars, and in Cuba in 1990-96, with an associated sharp fall in incidence and 
prevalence of type 2 diabetes [3; 4]. Perhaps the clearest evidence for the impact of positive 
energy balance in those with a predisposing genotype is provided by the Pima Indians, who 
had neither excess obesity nor excess diabetes when living as subsistence farmers [5; 6]. In 
1940, diabetes prevalence was similar to that of the general US population [7]. Thereafter, 
with cessation of an agricultural lifestyle together with food oversupply, there was a 
dramatic increase in rates of obesity, and the prevalence of type 2 diabetes in adult Pima 
Indians rose to 38% [8].  There was only a modest rise in prevalence in ethnically identical 
Pima Indians living in Mexico under nutritional conditions which limit adult weight gain [8]. 
 
Type 2 diabetes is commonly said to be a consequence of obesity. However, in the 1970s, 
when the average weight of the UK population was considerably less than at present, the 
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Whitehall study showed only a small association between obesity and type 2 diabetes [9]. At 
that time it was considered that there was no major effect of obesity on the development of 
common Type 2 diabetes [9-11]. Although this may seem surprising from a present day 
perspective, the risk of type 2 diabetes rises most steeply at very high BMI’s  and in 1980 
only 7% of the population had a BMI >30kg/m2 [12]. The effect of high BMI upon 
 
development of diabetes was simply not detectable. While this association with obesity is 
now apparent, it has not generally been recognised that diabetes risk rises steadily 
throughout the population weight distribution. The Nurses’ Health Study showed a four-fold 
increase in type 2 diabetes prevalence in women with BMI 23-25 compared to those with 
BMI less than 22kg/m2 [13]. In the UK Prospective Diabetes Study, which recruited between 
1977 and 1991, 36% of newly diagnosed individuals had a BMI less than 25 kg/m2 [14]. 
 
Conversely, 72% of people with BMI >40kg/m2 do not have diabetes [15]. 
 
The individual susceptibility to type 2 diabetes which clusters in families must be considered. 
The condition does not occur unless beta-cell function is no longer sufficient to        
overcome insulin resistance [16]. Genome wide association studies (GWAS) indicate that the 
vast majority of type 2 diabetes-associated genes are likely to have a beta-cell specific role, 
relating to impaired ability to cope with metabolic stress [17]. Although the molecular 
mechanisms remain to be defined, it is likely that a range of susceptibility to beta-cell 
damage exists with differences between individuals. 
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The pathologic basis of disease progression 
 
 
At diagnosis of type 2 diabetes, beta-cell function is typically reduced to 50% of normal by 
HOMA modelling and to a greater extent on dynamic testing [1; 18]. Despite initial impact of 
diet and oral glucose lowering therapy, observational studies have shown that disease 
progression is associated with inexorably declining beta-cell function and progression to 
insulin commencement with relatively minor changes in underlying insulin resistance.  Such 
observations have been made in the context of continuing weight gain [19]. 
 
Metabolic studies have enabled elucidation of dynamic changes in beta-cell function and 
insulin resistance over time. In contrast, absence of imaging modalities with sufficient 
resolution to image the beta-cell in situ has prevented determination of whether these 
changes are caused by dysfunction or true loss of beta-cell mass at a cellular level [20]. 
Moreover, satisfactory circulating markers of beta-cell death or proliferation are currently 
lacking [21]. 
 
Post mortem pancreatic pathology studies, based on presence of staining for insulin 
containing cells, have suggested that beta-cell mass is significantly reduced in type 2 
diabetes in comparison to age, sex and BMI-matched non-diabetic controls [2]. While it is 
accepted that increased apoptosis plays a role in decreased beta-cell mass over time, 
pancreatic pathology findings in a large cohort of European subjects indicate that apoptosis 
alone is insufficient to explain the profound islet dysfunction in established type 2 diabetes 
[22]. Other factors must contribute to the described decrease in cells which stain positive 
for insulin in the pancreatic islets. 
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Glucolipotoxicity 
 
 
In diabetes-prone rodent models of type 2 diabetes, the beta-cell fails during overfeeding in 
those with the genetic predisposition, and this genetic susceptibility to lipid availability is 
reflected in studies on isolated islets [23].  When fatty acid concentrations are elevated in 
vitro, lipid synthesis and storage within the beta-cell is favored and chronic exposure of the 
beta-cell to fatty acid excess directly impairs glucose-stimulated insulin secretion (Figure 
1)[24-26]. Prolonged exposure to elevated levels of fatty acids in vitro directly results in 
beta-cell stress and dysfunction [27]. 
 
Exposure of the INS1 beta-cell line to oleic acid brings about storage in intracytoplasmic 
vacuoles, whereas the saturated fatty acid palmitate induces expansion of the endoplasmic 
reticulum (Figure 1A&B) [27]. This is known to be associated with markers of endoplasmic 
reticulum stress, which are typically elevated in human beta-cells from individuals with type 
2 diabetes [28-30]. The more physiologic exposure to mixed saturated and unsaturated fatty 
acids decreases insulin secretion and subsequent removal of fatty acid from the medium 
allows return of insulin secretion over 24 hours (Figure 1C&D) [27]. Human islets also take  
up fatty acids avidly and incubation in 0.33 mmol/l palmitate leads to a very large increase  
in islet triglyceride content, associated with markedly impaired function  (Figure 1E&F)[25]. 
Once hyperglycemia occurs, the concomitant elevated glucose is likely to compound the 
metabolic insult [31]. 
 
Despite the growing body of in vitro and in vivo animal data [31] in support of an important 
role of glucolipotoxicity in type 2 diabetes pathogenesis and progression, human studies 
have proved more challenging. Hyperglycemia reversibly impairs insulin secretion in vivo 
[32; 33]. The combination of hyperglycemia and raised plasma free fatty acids has an 
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additive effect [34]. Prolonged Intralipid infusion severely impairs beta-cell function in 
subjects predisposed to develop type 2 diabetes [35]. Removal of excess lipid from the 
pancreas (by decreased supply in the face of  continuing oxidation for energy needs) at the 
same time as decreasing plasma VLDL1-triglyceride allows return of normal insulin secretion 
in early type 2 diabetes [36; 37]. The removable excess of intra-pancreatic triglyceride by 
weight loss has been shown to be specific to type 2 diabetes in a recent study using 
optimised pancreatic magnetic resonance imaging [38]. 
 
 
 
Beta-cell  dedifferentiation 
 
 
Loss of fully differentiated phenotype is a recently recognised  potential mechanism 
underlying loss of beta-cell function in type 2 diabetes [39-43]. The metabolic stress of chronic 
nutrient oversupply can lead to reduced expression or nuclear activity of key beta-cell 
transcription factors including Pdx1, Nkx6.1 and MafA [39-41]. This results in loss of critical 
end-differentiated genes including insulin itself in parallel with induction of ‘disallowed genes’ 
including lactate dehydrogenase and hexokinase [44]. Beta-cell dysfunction ensues due to a 
combination of decreased insulin biosynthesis and loss of physiological nutrient-secretion 
coupling. This has been demonstrated in a number of models of glucotoxicity including partial 
pancreatectomy with changes largely prevented by maintenance of normoglycemia [45]; and 
in beta-cells in vitro following chronic palmitate exposure [46]. 
 
The Accili group have proposed an important role of the FoxO transcription factors in type 2 
diabetes pathogenesis. Initially, enhanced FoxO1 nuclear translocation appears to maintain 
the activation state of a subset of beta-cell transcription factors, including MafA, preserving 
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glucose oxidation and suppressing fatty acid oxidation thus limiting mitochondrial stress [47]. 
Through this mechanism, FoxO1 is able to orchestrate a compensatory response aimed at 
preserving beta-cell function under metabolic stress (Figure 2). Establishment of chronic 
hyperglycemia, however, leads to FoxO1 degradation and beta-cell decompensation with 
impaired capacity for glucose oxidation and increased ability to oxidise palmitate. This has 
been described as ‘metabolic inflexibility’ with generation of toxic products including 
peroxides and impaired insulin secretion [47]. 
 
Lineage tracing studies in mice with beta-cell specific deletion of FoxO1 exposed to metabolic 
stressors, including ageing and multiple pregnancies, demonstrated that loss of beta-cell mass 
was due to dedifferentiation as opposed to death [41]. Whilst maintaining expression of the 
endocrine marker chromogranin A (ChgA), expression of insulin was lost in parallel with a 
number of key beta-cell transcription factors (PDX1, Nkx6.1 and MafA). Furthermore, lineage 
traced dedifferentiated cells (also referred to as ‘empty’ cells)  expressed a number of genes 
not normally associated with adult beta-cells, including mesenchymal markers (vimentin) and 
pancreatic progenitor markers such as neurogenin 3 (Figure 2). Relevance to type 2 diabetes 
was evidenced by the demonstration that progressive loss of FoxO1 was associated with a 
large number of ChgA+/insulin- cells in rodent models of type 2 diabetes. Given the inability to 
directly assess cellular pathologies in people with diabetes, translation of these studies to an 
understanding of human pathophysiology has been challenging. Although beta-cells cannot be 
genetically labelled for in situ lineage tracing studies in humans, rodent models [39; 41; 48] 
have enabled identification of specific transitional phenotypes which can be stained for in 
pathological pancreatic samples. These can help determine the characteristics and fate of 
human beta-cells during the course of clinical diabetes. 
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Supported by detailed quantitative human pathology analysis, it is now established that 
impaired beta-cell function in type 2 diabetes cannot be accounted for by increased apoptosis 
alone [22; 49]. Recent post mortem studies demonstrate that beta-cell dysfunction in type 2 
diabetes may be associated with degranulation and alterations in beta-cell phenotype. 
Expression of key beta-cell transcription factors, including PDX1 and MafA, is markedly 
reduced in type 2 diabetes, suggesting that dedifferentiation (defined by loss of canonical 
beta-cell markers) may contribute to impaired beta-cell function [50; 51]. Furthermore, 
expression of disallowed genes, including vimentin, has been detected in beta-cells from 
patients with type 2 diabetes, providing support for the observations in rodents made by 
Talchai et al  [41]. In a recent pancreas pathology study, ‘empty’ beta-cells were assessed by 
co-immunofluorescent staining for the endocrine secretory granule marker, synaptophysin, 
and all endocrine hormones (insulin, glucagon, somatostatin and pancreatic polypeptide) [52] 
as described in db/db and GIRKO mice [53]. Through employment of this approach and 
normalisation to beta-cell number, the study determined that there was a significant increase 
in the number of ‘empty’ or dedifferentiated endocrine cells in people with type 2 diabetes in 
comparison to non-diabetic controls (31.0 vs. 8.7%). Employing a similar approach, Butler et al 
determined that although altered beta-cell phenotypes were evident, this did not account for 
the beta-cell deficit in type 2 diabetes [54]. However, expression of beta-cell transcription 
factors was not assessed within this study, thus limiting complete determination of beta-cell 
(de)differentiation status. In contrast, Cinti et al were able to demonstrate that a number of 
beta-cells displayed altered subcellular localisation of Nkx6.1 and MafA, with expression 
almost exclusively within the cytoplasm [52]. These findings are consistent with work by 
Spijker et al and indicate a functional impairment (due to cellular localisation) of these key 
transcription factors in human diabetes [40]. The extent to which such alterations contribute 
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to beta-cell dysfunction remains to be determined. However, further work exploring the 
association between the stage of dedifferentiation and functionality is likely to yield key 
mechanistic insights. 
 
Studies exploring beta-cell dedifferentiation as a mechanism underlying dysfunction have, to 
date, been unable to elucidate the specific underlying signalling pathways. For example, it is 
not possible to determine separately the impact of hyperglycemia and dyslipidemia on beta- 
cell (de)differentiation status in db/db mice and pathological samples from human donors with 
diabetes. Recent studies have sought to explore the effects of individual stresses. For example, 
in a transgenic mouse model with an activating KATP channel mutation of beta-cells, nutrient- 
stimulated insulin secretion was prevented [39]. Hyperglycemia in this model was associated 
with beta-cell dedifferentiation, characterised by the loss of end-differentiated beta-cell 
markers (Pdx1, MafA). In an ex vivo human islet lipotoxicity model, incubation with palmitate 
led to beta-cell dysfunction associated with loss end-differentiated phenotype evidenced by 
reduced levels of key beta-cell transcription factors [46]. 
 
 
 
 
Hyperglucagonemia in type 2 diabetes 
 
 
 
Type 2 diabetes has long been recognised to be a dual hormonal disorder with stimulation 
of hepatic glucose production by aberrant post-prandial hyperglucagonemia playing an 
important role in overall hyperglycemia [55; 56]. It remains unknown whether this state of 
relative glucagon over-secretion is driven by increased alpha-cell mass or simply increased 
function. Henquin et al observed no increases in alpha-cell mass in patients with type 2 
diabetes, concluding that relative hyperglucagonemia was likely being driven by reduced 
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beta-cell mass and subsequent alterations in the inhibitory actions beta-cells exert on alpha 
cells [57]. In contrast, Yoon et al observed that reduced beta-cell mass was associated with 
expansion of the alpha-cell mass in a different cohort of patients with type 2 diabetes [58]. 
Although it was proposed that increased alpha-cell mass may be a driver of 
hyperglucagonemia, a role for reduced beta-cell paracrine signalling cannot be excluded in 
this study. 
 
 
Given the limitations such cross sectional human studies pose, definitive evidence for 
changes in alpha-cell mass have largely been provided by rodent studies, with recent 
evidence proposing a potential role for beta-to alpha-cell conversion as a mechanism 
underlying this phenomenon [39; 53]. Through employment of the Fox01 ablation model, 
Talchai et al were able to demonstrate that, following metabolic stress, an increase in 
plasma and pancreatic glucagon was associated with beta-to-alpha cell conversion, as 
determined by glucagon expression in beta-derived cells [41]. In support of this, and a role 
for hyperglycaemia in these plasticity events, Brereton et al describe beta-to-alpha 
conversion in the KATP transgenic mouse model [39]. Although describing similar fate 
switching events, this study observed a number of bi-hormonal cells (insulin/glucagon co- 
expressing), indicating a direct conversion. In contrast, Talchai et al observe that expression 
of glucagon in beta-derived-cells only occurs once insulin is lost, with no co-expression 
evident. These observations may possibly be explained by the differences in each of the 
transgenic models used, and subsequent variations in the nature and timing of beta-cell 
stress. What remains consistent, however, is that both studies provide evidence for a shift in 
endocrine phenotype following loss of key beta-cell transcription factors. 
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Beta-cell dedifferentiation, characterised by the loss of beta-cell specific markers including 
Pdx1, Nkx6.1 and MafA, may enable conversion towards other pancreatic endocrine 
phenotypes which are less susceptible to nutrient-induced mitochondrial and endoplasmic 
reticulum stress [59]. This raises the possibility that beta-cell identity may be fragile and that 
metabolic stress eliminates factors which normally repress non-beta-cell identities. In 
support of this, deletion of Pdx1 in adult rodents leads to severe hyperglycemia in tandem 
with ultrastructural and physiological alpha-cell characteristics in a large fraction of the beta-
cells [48]. These data are in line  with beta-to-alpha-cell fate-switching events following loss 
of beta-cell specific transcription factors subsequent to chronic hyperglycemia [39]. 
Collectively, these studies indicate that alpha-cell and potentially other endocrine cell 
phenotypes may be ‘default’ lineages and that loss of critical beta-cell factors which 
suppress non-beta-cell related genes, including glucagon, during type 2 diabetes 
pathogenesis may lead to a shift in endocrine phenotype from beta-to alpha-cell [39; 41; 
48]. In light of recent data from Marroqui et al demonstrating that alpha-cells are more 
resistant to metabolic stress, it is possible that beta-alpha-cell transition during diabetes 
may be a defence mechanism to maintain cellular mass [59].   As reversal of type 2 diabetes 
is associated with fall to normal of fasting plasma glucagon levels at the same time as return 
of normal beta cell function the in vivo human studies may be reflecting redifferentiation of 
beta-cells. No change in plasma glucagon is seen in people with normal glucose tolerance 
during similar weight loss [60]. 
 
 
 
In support of earlier work by White et al [43], a recent study observed an 8-fold increased 
frequency of insulin positive cells co-expressing glucagon in tissue obtained from patients with 
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type 2 diabetes, indicating such beta-cell plasticity occurs in human diabetes [40]. It was 
determined that half the bi-hormonal (insulin+ /glucagon+) cells were negative for Nkx6.1. 
Furthermore, cytoplasmic localisation of Nkx6.1 was observed, a phenotype not evident in 
patients without diabetes. This was confirmed by the demonstration that a number of cells 
with cytoplasmic Nkx6.1 expression co-expressed glucagon [52], indicating a role for Nkx6.1 in 
repressing the alpha-cell programme, as described in vitro [61]. Nkx6.1+/glucagon+/insulin- 
cells were also identified, indicating that factors other than Nkx6.1 are critical to these 
phenotypic transitions [40]. 
 
 
 
Given the nature of these cross sectional studies, interpretation must be cautious. For 
example, it cannot be ruled out that bi-hormonal cells reflect beta-cell neogenesis.  However, 
given that beta-cell neogenesis has been described as originating close to and within ducts (2, 
[62], and associated bi-hormonal cells were localised to single and small clusters of beta-cells 
rather than within established islets [62], this appears unlikely. Also, Nkx6.1 is mis-localised 
(cytoplasm) in glucagon positive cells [52]. Although these post-mortem studies cannot 
provide definitive evidence, a contributory role for beta-to alpha-cell conversion in 
hyperglucagonemia in human diabetes is supported (Figure 2). 
 
 
 
 
 
Lessons on beta-cell plasticity from reversing type 2 diabetes 
 
 
 
The clearest data on the time course of recovery of beta-cell function following calorie 
restriction in type 2 diabetes have been provided by the Counterpoint study. In this, 
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observations were made at 1, 4 and 8 weeks after commencing a very low calorie diet [36]. 
After one week there was no improvement in the first phase insulin response to a stepped 
insulin secretion test with arginine (SISTA). This is especially significant as fasting plasma 
glucose had already normalised as a consequence of the very rapid return of normal hepatic 
insulin sensitivity. Hence the glucotoxicity component had been removed, and could no 
longer be exerting a major effect in suppressing first phase insulin response. The effect of 
raised glucose concentrations in inhibiting insulin secretion is known to be rapidly induced 
and removed [32]. Similarly, other suggested mechanisms of stress-induced beta-cell 
dysfunction should be rapidly reversible. For instance, the apparent mitochondrial 
dysfunction of type 2 diabetes is seen only when fasting plasma glucose is above 8 mmol/l 
[63] and is rapidly corrected by suppression of plasma fatty acid levels [64]. Reversal of 
oxidative stress and endoplasmic reticulum stress is also associated with rapid restoration of 
normal beta-cell function [27; 65]. 
 
 
By 4 weeks into the Counterpoint study a first phase insulin response could be seen in the 
group as a whole, and by 8 weeks this was well within the normal range and significantly 
improved from baseline. The slow normalisation of first phase insulin response over 8 weeks 
was mirrored by a slow normalisation of total intra-pancreatic fat [36]. Over this extended 
time course, the intra-pancreatic triglyceride concentration gradually declined to the same 
level as in non-diabetic control subjects [36]. The parallel time courses of the fall in excess 
triglyceride within the pancreas and the recovery of beta-cell function are suggestive but  
not conclusive of cause and effect. 
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It had to be considered whether the fall in intra-pancreatic triglyceride content could merely 
reflect the very considerable weight loss and not be related to restoration of beta-cell 
function. In order to determine whether weight loss also brought about a fall in intra- 
pancreatic triglyceride content in normoglycemic individuals or whether it was specific to 
type 2 diabetes, a further clinical study was conducted. The intra-pancreatic triglyceride 
content in a group of people about to undergo weight loss by gastric bypass surgery was 
quantified both before and 8 weeks after surgery [38]. Approximately 13% weight loss 
occurred both in those with normal glucose tolerance and those with type 2 diabetes. The 
former showed no change in intra-pancreatic triglyceride, whereas those with type 2 
diabetes had higher levels at baseline which fell to normal. At the same time, first phase 
insulin response was restored to normal. This study demonstrates that there is an increased 
pool of triglyceride within the pancreas in people with type 2 diabetes and that substantial 
weight loss is associated with clearance of this triglyceride excess. As discussed above, 
exposure of beta-cells to excess saturated fatty acid causes avid uptake and decreases 
insulin secretory response to a change in glucose concentration. It appears possible that the 
gradual clearance of excess triglyceride from the pancreas might be causally linked with the 
recovery of insulin secretion. Quantitative comparison with measurements on isolated islets 
in vitro is not currently feasible. 
 
 
Weight loss of 15 kg in individuals with type 2 diabetes leaves many people still in the obese 
category. It has to be considered that fat removed from liver and pancreas by short term 
hypocaloric dieting might gradually be replaced from the remaining excess in subcutaneous 
and visceral depots. If so, follow up might be hypothesised to reveal re-accumulation of 
intra-pancreatic fat with or without decline in beta-cell function. This has been examined by 
16 
CONFIDENTIAL-For Peer Review Only 
 
Diabetes Care Page 16 of 31 
 
 
 
 
six months follow up after acute weight loss of people with type 2 diabetes [37]. The group 
which achieved post-weight loss fasting plasma glucose of <7 mmol/l demonstrated intra- 
pancreatic triglyceride content falling to normal levels. Critically, weight remained stable 
over 6 months. First phase insulin response became and remained normal in this group. 
There was no reaccumulation of fat in either pancreas of liver even though mean BMI was 
30kg/m2  [37]. 
 
 
Return to normal blood glucose control after weight loss is strongly related to duration of 
type 2 diabetes. Whereas 87% of a short-duration group (<4 years) achieved non-diabetic 
fasting plasma glucose levels immediately after acute weight loss, only 50% of a long- 
duration group (8-23 years) did so [66]. In an audit of outcome following bariatric surgery, 
HbA1c of <43mmol/mol (6.1%) was achieved by 62% and 26% respectively in those with 
duration of diabetes <4 or >8 years respectively [60], reflecting previous observations [67]. 
The Scandinavian Obesity Study also confirmed the importance of duration of diabetes in 
rates of reversal of diabetes at 2 years [68]. As the duration of diabetes increases, it appears 
that a point of no return is passed with progression to fully differentiated alternative 
endocrine lineages (either directly or following dedifferentiation) and/or irreversible 
apoptosis (Figure 2). 
 
 
 
 
Redifferentiation provides an attractive potential underlying mechanism for recovery of 
beta-cell function following reduction in islet fat content over the time course observed in 
vivo in humans. It can be hypothesised that this time course is too slow for reversal of acute 
stress-induced dysfunction and too fast for beta-cell neogenesis. The dedifferentiated state 
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could be considered as providing a ‘hideaway’ until the metabolic insult subsides, offering 
an opportunity for restoration of end-differentiated state following alleviation of metabolic 
stresses. This ‘therapeutic window’ appears limited given the failure to rescue beta-cell 
function in subjects with long standing diabetes [60]. It indicates the potential progressive 
nature of dedifferentiation, with a point of no return in (de)differentiation status and/or 
apoptosis and subsequent irreversibility of loss of function/mass. An association may be 
postulated between the extent of these abnormalities, stage of diabetes and potential for 
reversal through beta-cell re-differentiation (Figure 2). 
 
 
 
The potential for re-differentiation as a mechanism underlying restoration of beta-cell 
function in type 2 diabetes is illustrated by restoration of beta cell function by  intensive 
insulin therapy in a rodent model of hyperglycemia [42]. This restoration in beta-cell 
function was associated with beta-cell re-differentiation, characterised by increased levels 
of mature beta-cell markers including insulin, Pdx1 and MafA. These observations support 
the proposition that, following removal of hyperglycemia and change in lipid metabolism 
achieved by intensive insulin therapy, beta-cell re-differentiation can occur and contribute 
to diabetes reversal. These studies were extended to demonstrate a restoration in 
sulfonylurea-sensitive insulin secretion, similar to that observed in patients with type 2 
diabetes following intensive insulin therapy. 
 
 
 
It is striking that strategies targeting restored pancreatic insulin secretion directly have not 
been shown to be disease-modifying in terms of restoring functional beta-cell mass, 
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although the ADOPT study demonstrated greater preservation of beta-cell function with the 
insulin sensitiser rosiglitazone compared to sulfonylurea secretagogue therapy. Use of 
exenatide over 3 years caused considerable weight loss and brought about some return of 
beta cell function [69]. Overall it appears that decreased beta-cell exposure to nutrient 
excess facilitates reversal of acute dysfunction and adaptive dedifferentiation (45). There is 
a need for specific therapies targeted towards reversal of beta-cell dedifferentiation  [70- 
72]. The major question of how function might be returned after apparent end stage de- 
differentiation requires to be addressed. 
 
 
 
Identification is underway of candidate pathways that could be targeted to reverse beta-cell 
dedifferentiation associated dysfunction [73]. A small molecule inhibitor of the TGF-beta 
receptor (Alk5) was shown to be capable of reversing beta-cell dedifferentiation in islets 
isolated from mice with extreme diabetes, utilising Urocortin 3 as a marker for mature beta- 
cells. Potential translation to human disease was indicated by incubation of isolated human 
islets with ALK5 inhibitor, bringing about increased expression levels of a number of mature 
beta-cell markers including insulin, Pdx1 and MafA.  However, administration of ALK5 
inhibitor to diabetic animals failed to improve glycaemic control, causing an overall 
deterioration in health. This highlights the requirement for development of pathway-specific 
therapeutics to restore mature, functional beta-cells if a successful pharmacological 
approach to controlling type 2 diabetes is to be developed. 
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A unifying hypothesis 
 
 
 
The 2008 Twin Cycle Hypothesis could potentially allow synthesis of the in vivo and in vitro 
observations [36-38]. The hypothesis postulated that chronic positive calorie balance, in the 
presence of pre-existing peripheral insulin resistance and hence hyperinsulinemia, would 
bring about steady accretion of intra-hepatic triglyceride and initiate linked vicious cycles 
(Figure 3) [74]. Whilst the mechanisms underlying the liver cycle are well established, the 
recent in vitro work on beta-cell dedifferentiation provides an attractive potential 
explanation for the operation of the pancreas cycle [74]. The increased plasma very low 
density lipoprotein-triglyceride of type 2 diabetes is postulated to bring about fat 
accumulation and beta-cell stress such that plasma glucose remains elevated for longer after 
meals.  The consequent  effects of over-supply of saturated fatty acids on beta-cell 
dedifferentiation could cause gradually decreasing ability to mount an acute insulin response 
to eating. The liver and pancreas cycles mutually interact and reinforce each other.               
At a critical point, the beta cell will fail, resulting in type 2 diabetes. All of these predictions 
of the 2008 hypothesis have now been observed in vivo [36-38]. 
 
 
Although most people who develop type 2 diabetes are overweight or obese by BMI criteria 
the condition is not uncommon in those within the normal range (36% in the UKPDS 
population). Direct observational data suggests that a threshold effect operates, whereby 
ectopic fat accumulation only occurs when an individual’s capacity to store fat safely in the 
subcutaneous compartment is exceeded – the Personal Fat Threshold concept [37; 75]. BMI, 
which was originally developed as a population metric, may mislead when applied to the 
individual if their adult weight gain is within the normal range. The concept could also 
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explain the predisposition of some ethnic groups, notably south Asians, to develop type 2 
diabetes at relatively low BMI. 
 
 
The recent observations upon lack of restoration of the first phase insulin response in long 
duration type 2 diabetes after substantial weight loss [37] can now be explained in terms of 
beta cell dedifferentiation. The process of losing the specialised function to produce insulin 
can be postulated to reach a point beyond which removal of the initial insult of excess fatty 
acid is not followed by the restoration of nuclear expression of key beta-cell specific 
transcription factors and recovery of differentiated glucose-responsive insulin secretion 
(Figure 2). 
 
 
Type 2 diabetes may now be seen as a potentially reversible state associated with 
longstanding nutrient overload in susceptible individuals. The beta-cell dysfunction and loss 
of end-differentiated beta-cell phenotype can be restored by substantial weight loss. After 
approximately 10 years, the onward march of beta-cell dedifferentiation appears likely to 
precipitate irreversible loss of insulin secretion - unless substantial decrease in body weight 
is achieved. 
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Legends to Figures 
Figure 1 
Interaction of fatty acids with beta cell ultrastructure and function: A: Effects of exposure to 
0.33mmol/l oleate or B: 0.33mmol/l palmitate upon the ultrastructure of INS-1 cells. Original 
photomicrographs provided by Dr Katherine Pinnick and Anne Clark [27]. C: Exposure of mouse islets 
to oleate or palmitate (0.5mmol/l) for 48h significantly impaired glucose-stimulated insulin secretion 
(data from K. Pinnick [27]). D: Impairment in glucose-stimulated insulin secretion in mouse islets 
brought about by incubation for 72h in a fatty acid mixture (0.5mmol/l 1:1/oleate:palmitate)          
was not present following 48h exposure followed by 24h in fatty acid-free media (reproduced with 
permission from [27]). E: Effect of exposure of human islets to 0.33mmol/l palmitate on islet 
triglyceride content and F: islet glucose medicated insulin secretion. Graphs E and F are reproduced 
with permission from [25]. 
 
 
 
 
Figure 2 
 
Schematic representation of possible stages of beta-cell fate changes associated with diabetes 
progression: During metabolic stress, FoxO1 translocates to the nucleus to orchestrate a 
compensatory response to help preserve glucose oxidation and suppress fatty acid oxidation. FoxO1 
target genes include beta-cell transcription factors MafA and NeuroD, which through continued 
activation of insulin expression help preserve beta-cell function under metabolic stress. Continued 
stress leads to loss and/or cytoplasmic translocation of beta-cell transcription factors (Nkx6.1 and 
MafA) and reduced/lost insulin expression. Analysis of human and rodent data indicates that cells, at 
this stage of diabetes, can undergo significant plasticity events that involves the (re)expression of 
‘disallowed genes’. At this stage, cells can be characterised by two distinct identities: i) Hormone 
‘empty’ cells that may express progenitor (Ngn3 and Oct4) and mesenchymal (Vimentin) proteins  
and ii) transdifferentiated/bi-hormonal cells that express other endocrine hormones, including 
glucagon. Pre-clinical data indicate that recovery of beta-cell failure at this stage of diabetes can be 
achieved through redifferentiation of dedifferentiated/transdifferentiated cells, a phenomenon that 
has been implied clinically also following calorie restriction diet. Sustained metabolic stress may 
result in irreversible beta-cell failure through apoptosis (dedifferentiated cells) and/or established 
alpha-cell differentiation, however this has yet to be be confirmed in humans. Solid arrows indicate 
observed rodent and human phenotypes and broken arrows indicate potential cellular pathways that 
may account for beta-cell loss and/or recovery. 
 
 
Figure 3 
 
During long term excess calorie intake, especially in the presence of muscle insulin 
resistance, the raised plasma insulin levels will expedite chronic excess calorie storage from 
carbohydrate via de novo lipogenesis. This will promote storage of fat in the liver very 
gradually over years and liver insulin resistance, with a consequent tendency for a small 
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increase in plasma glucose (as shown by the Whitehall II study [76]). In turn, insulin secretion will 
increase to control plasma glucose. The further increased insulin levels will bring about a self-
reinforcing vicious cycle. The increased liver fat will inevitably lead to an increased rate of export of 
VLDL triglyceride from the liver. Along with all other tissue, islets will be therefore exposed to higher 
rates of fatty acid supply and the exposure of pancreatic endocrine cells to fatty acids and their 
metabolites will increase. This is postulated to bring about endoreticulum stress in susceptible 
individuals, and eventually beta cell dedifferentiation, with relative inhibition of meal insulin 
secretion. The vicious cycles are postulated to interact over many years. At a personal threshold 
level, it is postulated that the beta-cells can no longer compensate, and plasma glucose levels will 
then rise relatively rapidly. The Figure is redrawn from reference [74] and reproduced from 
reference [77]. 
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Figure 1 
Interaction of fatty acids with beta cell ultrastructure and function: A: Effects of exposure to 0.33mmol/l 
oleate or B: 0.33mmol/l palmitate upon the ultrastructure of INS-1 cells. Original photomicrographs 
provided by Dr Katherine Pinnick and Anne Clark [27]. C: Exposure of mouse islets to oleate or palmitate 
(0.5mmol/l) for 48h significantly impaired glucose-stimulated insulin secretion (data from K. Pinnick [27]). 
D: Impairment in glucose-stimulated insulin secretion in mouse islets brought about by incubation for 72h in 
a fatty acid mixture (0.5mmol/l 1:1/oleate:palmitate) was not present following 48h exposure followed by 
24h in fatty acid-free media (reproduced with permission from [27]). E: Effect of exposure of human islets 
to 0.33mmol/l palmitate on islet triglyceride content and F: islet glucose medicated insulin secretion. Graphs 
E and F are reproduced with permission from [25]. 
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Figure 2 
Schematic representation of possible stages of beta-cell fate changes associated with diabetes progression: 
During metabolic stress, FoxO1 translocates to the nucleus to orchestrate a compensatory response to help 
preserve glucose oxidation and suppress fatty acid oxidation. FoxO1 target genes include beta-cell 
transcription factors MafA and NeuroD, which through continued activation of insulin expression help 
preserve beta-cell function under metabolic stress. Continued stress leads to loss and/or cytoplasmic 
translocation of beta-cell transcription factors (Nkx6.1 and MafA) and reduced/lost insulin expression. 
Analysis of human and rodent data indicates that cells, at this stage of diabetes, can undergo significant 
plasticity events that involves the (re)expression of ‘disallowed genes’. At this stage, cells can be 
characterised by two distinct identities: i) Hormone ‘empty’ cells that may express progenitor (Ngn3 and 
Oct4) and mesenchymal (Vimentin) proteins and ii) transdifferentiated/bi-hormonal cells that express other 
endocrine hormones, including glucagon. Pre-clinical data indicate that recovery of beta-cell failure at this 
stage of diabetes can be achieved through redifferentiation of dedifferentiated/transdifferentiated cells, a 
phenomenon that has been implied clinically also following calorie restriction diet. Sustained metabolic stress 
may result in irreversible beta-cell failure through apoptosis (dedifferentiated cells) and/or established alpha-
cell differentiation, however this has yet to be be confirmed in humans. Solid arrows indicate observed 
rodent and human phenotypes and broken arrows indicate potential cellular pathways that may account for 
beta-cell loss and/or recovery. 
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Figure 3 
During long term excess calorie intake, especially in the presence of muscle insulin resistance, the raised 
plasma insulin levels will expedite chronic excess calorie storage from carbohydrate via de novo lipogenesis. 
This will promote storage of fat in the liver very gradually over years and liver insulin resistance, with a 
consequent tendency for a small increase in plasma glucose (as shown by the Whitehall II study [76]). In 
turn, insulin secretion will increase to control plasma glucose. The further increased insulin levels will bring 
about a self-reinforcing vicious cycle. The increased liver fat will inevitably lead to an increased rate of  
export of VLDL triglyceride from the liver. Along with all other tissue, islets will be therefore exposed to 
higher rates of fatty acid supply and the exposure of pancreatic endocrine cells to fatty acids and their 
metabolites will increase. This is postulated to bring about endoreticulum stress in susceptible individuals, 
and eventually beta cell dedifferentiation, with relative inhibition of meal insulin secretion. The vicious cycles 
are postulated to interact over many years. At a personal threshold level, it is postulated that the beta-cells 
can no longer compensate, and plasma glucose levels will then rise relatively rapidly. The Figure is redrawn 
from reference [74] and reproduced from reference [77]. 
 
254x190mm (96 x 96 DPI) 
 
